# Akebia Therapeutics, Inc.: filings

AKBA · Nasdaq · CIK 1517022 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/akba.md) · [Financials](/companies/akba/financials.md) · [Filings](/companies/akba/filings.md) · [Insiders](/companies/akba/insiders.md)

## Reports and events: 251 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (4 326, 8-K 165, 3 42, 10-Q 38, SC 13G/A 32, 144 28, 425 25, DEFA14A 22, CT ORDER 20, 424B5 17, S-8 16, SC 13G 16, DEF 14A 13, 10-K 12, CORRESP 12, UPLOAD 11, 4/A 8, SC 13D/A 7, EFFECT 6, 8-K/A 5, SC 13D 5, ARS 4, S-1/A 4, PRE 14A 3, S-3 3, 5 2, FWP 2, S-3ASR 2, S-4/A 2, SCHEDULE 13G/A 2, SEC STAFF LETTER 2, 10-K/A 1, 424B3 1, 424B4 1, 8-A12B 1, CERTNAS 1, D 1, D/A 1, DEFR14A 1, DRS 1, DRS/A 1, NT 10-K 1, NT 10-Q 1, POS AM 1, POSASR 1, PRER14A 1, S-1 1, S-1MEF 1, S-3/A 1, S-4 1, SCHEDULE 13G 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-23 | 16:06 ET | [8-K](/filings/0001517022-26-000075.md) | 3.01 Delisting notice | 0001517022-26-000075 |
| 2026-10-14 | 11:57 ET | [8-K](/filings/0001517022-26-000071.md) | 5.02 Departure or appointment of officers or directors | 0001517022-26-000071 |
| 2026-08-05 | 20:10 ET | [10-Q](/filings/0001517022-26-000051.md) | Quarterly report, period 2026-06-30 | 0001517022-26-000051 |
| 2026-08-05 | 20:09 ET | [8-K](/filings/0001517022-26-000050.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001517022-26-000050 |
| 2026-06-30 | 12:05 ET | [8-K](/filings/0001517022-26-000047.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001517022-26-000047 |
| 2026-06-22 | 20:16 ET | [8-K](/filings/0001517022-26-000043.md) | 5.07 Shareholder vote results | 0001517022-26-000043 |
| 2026-05-07 | 11:24 ET | [10-Q](/filings/0001517022-26-000039.md) | Quarterly report, period 2026-03-31 | 0001517022-26-000039 |
| 2026-05-07 | 11:05 ET | [8-K](/filings/0001517022-26-000038.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001517022-26-000038 |
| 2026-04-28 | 20:12 ET | [DEF 14A](/filings/0001517022-26-000034.md) | Proxy statement, period 2026-04-28 | 0001517022-26-000034 |
| 2026-04-01 | 20:48 ET | [8-K](/filings/0001517022-26-000024.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001517022-26-000024 |
| 2026-02-26 | 12:35 ET | [10-K](/filings/0001517022-26-000020.md) | Annual report, period 2025-12-31 | 0001517022-26-000020 |
| 2026-02-26 | 12:04 ET | [8-K](/filings/0001517022-26-000019.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001517022-26-000019 |
| 2026-01-30 | 13:34 ET | [8-K](/filings/0001517022-26-000008.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001517022-26-000008 |
| 2026-01-12 | 13:04 ET | [8-K](/filings/0001517022-26-000003.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001517022-26-000003 |
| 2025-12-01 | 12:08 ET | [8-K](/filings/0001517022-25-000051.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001517022-25-000051 |
| 2025-11-17 | 12:54 ET | [8-K](/filings/0001517022-25-000048.md) | 1.01 Entry into a material agreement | 0001517022-25-000048 |
| 2025-11-10 | 12:36 ET | [10-Q](/filings/0001517022-25-000046.md) | Quarterly report, period 2025-09-30 | 0001517022-25-000046 |
| 2025-11-10 | 12:04 ET | [8-K](/filings/0001517022-25-000045.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001517022-25-000045 |
| 2025-10-28 | 20:37 ET | [8-K](/filings/0001517022-25-000040.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001517022-25-000040 |
| 2025-08-07 | 11:38 ET | [10-Q](/filings/0001628280-25-038600.md) | Quarterly report, period 2025-06-30 | 0001628280-25-038600 |
| 2025-08-07 | 11:06 ET | [8-K](/filings/0001517022-25-000034.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001517022-25-000034 |
| 2025-06-13 | 11:21 ET | [8-K](/filings/0001517022-25-000030.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0001517022-25-000030 |
| 2025-05-08 | 11:29 ET | [10-Q](/filings/0001628280-25-023460.md) | Quarterly report, period 2025-03-31 | 0001628280-25-023460 |
| 2025-05-08 | 11:04 ET | [8-K](/filings/0001517022-25-000027.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001517022-25-000027 |
| 2025-04-29 | 20:03 ET | [DEF 14A](/filings/0001517022-25-000023.md) | Proxy statement, period 2025-04-29 | 0001517022-25-000023 |
| 2025-03-20 | 20:48 ET | [8-K](/filings/0001193125-25-059327.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-059327 |
| 2025-03-13 | 11:27 ET | [10-K](/filings/0001628280-25-012470.md) | Annual report, period 2024-12-31 | 0001628280-25-012470 |
| 2025-03-13 | 11:08 ET | [8-K](/filings/0001517022-25-000017.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001517022-25-000017 |
| 2025-02-07 | 13:16 ET | [8-K](/filings/0001517022-25-000010.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity | 0001517022-25-000010 |
| 2025-01-13 | 13:05 ET | [8-K](/filings/0001517022-25-000004.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001517022-25-000004 |
| 2024-11-07 | 12:16 ET | [10-Q](/filings/0001628280-24-045979.md) | Quarterly report, period 2024-09-30 | 0001628280-24-045979 |
| 2024-11-07 | 12:05 ET | [8-K](/filings/0001517022-24-000075.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001517022-24-000075 |
| 2024-10-22 | 12:05 ET | [8-K](/filings/0001517022-24-000070.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001517022-24-000070 |
| 2024-10-16 | 11:36 ET | [8-K](/filings/0001517022-24-000067.md) | 1.01 Entry into a material agreement | 0001517022-24-000067 |
| 2024-08-08 | 11:52 ET | [10-Q](/filings/0001628280-24-035879.md) | Quarterly report, period 2024-06-30 | 0001628280-24-035879 |
| 2024-08-08 | 11:06 ET | [8-K](/filings/0001517022-24-000065.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001517022-24-000065 |
| 2024-07-11 | 10:05 ET | [8-K](/filings/0001517022-24-000061.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement | 0001517022-24-000061 |
| 2024-06-24 | 13:03 ET | [8-K](/filings/0001517022-24-000059.md) | 5.02 Departure or appointment of officers or directors | 0001517022-24-000059 |
| 2024-06-10 | 20:09 ET | [8-K](/filings/0001517022-24-000057.md) | 5.07 Shareholder vote results | 0001517022-24-000057 |
| 2024-05-09 | 11:05 ET | [10-Q](/filings/0001628280-24-021945.md) | Quarterly report, period 2024-03-31 | 0001628280-24-021945 |
| 2024-05-09 | 11:03 ET | [8-K](/filings/0001517022-24-000050.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001517022-24-000050 |
| 2024-04-25 | 21:17 ET | [DEF 14A](/filings/0001517022-24-000045.md) | Proxy statement, period 2024-04-25 | 0001517022-24-000045 |
| 2024-04-23 | 12:32 ET | [8-K](/filings/0001517022-24-000035.md) | 2.03 New direct financial obligation | 0001517022-24-000035 |
| 2024-04-16 | 11:33 ET | [8-K](/filings/0001517022-24-000033.md) | 1.01 Entry into a material agreement | 0001517022-24-000033 |
| 2024-03-28 | 00:35 ET | [8-K](/filings/0001517022-24-000031.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001517022-24-000031 |
| 2024-03-15 | 20:05 ET | [8-K](/filings/0001193125-24-069123.md) | 5.02 Departure or appointment of officers or directors | 0001193125-24-069123 |
| 2024-03-14 | 21:19 ET | [10-K](/filings/0001628280-24-011270.md) | Annual report, period 2023-12-31 | 0001628280-24-011270 |
| 2024-03-14 | 20:18 ET | [8-K](/filings/0001517022-24-000029.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001517022-24-000029 |
| 2024-02-13 | 13:00 ET | [8-K](/filings/0001517022-24-000019.md) | 5.02 Departure or appointment of officers or directors | 0001517022-24-000019 |
| 2024-01-30 | 13:05 ET | [8-K](/filings/0001517022-24-000014.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity | 0001517022-24-000014 |

Page 1 of 6. [Older](/companies/akba/filings.md?page=2)
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:13 ET. No prices; not investment advice.